Efemoral Medical Announces Series A1 Funding

New funding will support increasing enrollment in its ongoing first-in-human trial, EFEMORAL I LOS ALTOS, Calif., Dec. 13, 2022 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the closing of its $4.9M preferred Series A1…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.